Allergies are no longer a seasonal inconvenience. Urbanization, air pollution, longer pollen seasons and changing lifestyles are pushing allergic conditions higher worldwide. According to Grand View Research, the global allergy diagnostics and therapeutics market was valued at USD 37.1 billion in 2025. It is estimated at USD 40.2 billion in 2026 and projected to reach USD 78.0 billion by 2033, a CAGR of 10.0%.

This post covers the market structure and trends, the regions leading it, the companies competing in it, and what it means for investors and business leaders.

Market Breakdown & Key Trends

Therapeutics dominate, but diagnostics are accelerating

Therapeutics held about 82.9% of revenue in 2025. Epinephrine anchors the segment because it works fast and reliably in anaphylaxis, and it is inexpensive and has decades of clinical trust behind it. Immunotherapy is the more important growth story. The FDA's February 2024 approval of Xolair (omalizumab) for IgE-mediated food allergy in certain adults and children aged one and older is an example of newer biologics meeting needs that were previously unmet.

Diagnostics are expected to post the highest CAGR. Clinicians increasingly want precise, early identification of allergen sensitivities so they can target treatment. Beckman Coulter Life Sciences' April 2025 launch of a next-generation Basophil Activation Test for research use shows where the field is heading. It aims to identify food allergies from a simple blood draw, with no direct allergen exposure for the patient.

Go Deeper! Ask Prism AI about the Global Allergy Diagnostics and Therapeutics Market. Get instant answers to questions related to market sizing, growth drivers and their impact, and more.

Inhaled allergens lead; drug allergies are the faster climber

Inhaled allergies accounted for roughly 49.9% of the market in 2025. Dust mites, pet dander, mold spores and extended pollen seasons are all contributing. Drug allergies are expected to grow fastest, helped by better treatment options and rising patient awareness.

In vitro testing leads the test mix

In vitro tests held about 52.3% of revenue in 2025. They are minimally invasive and cost-effective, and they fit well with lab automation and reagent rental models. Microfluidics, biosensors and lab-on-a-chip devices are enabling point-of-care testing with minimal sample volume. Combined with AI and analytics, they could help predict individual reactions. In vivo tests such as skin prick tests are still expected to grow steadily because they are convenient, safe and economical.

Trends worth watching

• Rising prevalence. The report cites WHO data indicating that roughly 1 in 4 U.S. children and 1 in 3 U.S. adults have a seasonal allergy. Nearly 6% of U.S. children and adults have a food allergy.
• Precision diagnostics. Component-resolved diagnostics (CRD), molecular profiling and multiplex assays are improving accuracy. India's Metropolis Healthcare launched a fourth-generation, AI-assisted CRD platform.
• Funding for better food allergy tests. Allergios received a HealthHolland grant in October 2024 to help validate GranulEye. The test aims to diagnose true clinical peanut allergy rather than mere sensitization.
• Penicillin allergy testing. The CDC reports that about 10% of U.S. patients claim a penicillin allergy, but fewer than 1% are truly allergic. That gap supports demand for accurate testing.

Regional Leaders

North America: the clear leader

North America captured 36.6% of global revenue in 2025, and the U.S. was the largest country market. The region combines strong healthcare infrastructure, tight regulatory frameworks, heavy R&D investment and a large volume of clinical trials. Two recent examples:

• In October 2025, RAPT Therapeutics started a Phase 2b trial of ozureprubart for IgE-mediated food allergies at about 30 sites across the U.S. and Canada.
• In October 2024, the FDA approved the AccuTest allergy skin testing device, which has smaller tines intended to improve precision and reduce discomfort.

Europe: regulation and reimbursement as growth enablers

Europe's growth rests on rising allergy prevalence, preventive-care policies and wider access to biologics and sublingual immunotherapy (SLIT). The EU In Vitro Diagnostic Regulation (IVDR) raises the quality bar. In the UK, research funded by King's College London and Guy's and St Thomas' NHS Foundation Trust is exploring a cheaper, more accurate milk allergy test for children. Germany's research strength and supportive reimbursement make it a key market.

Asia Pacific: pollution and population drive demand

Japan, China and India stand out. Japan faces intense seasonal pollen and an aging population. In China, urbanization and pollution are increasing allergy incidence, and a Beijing study found about 30% prevalence of pollen-food allergy syndrome among pollinosis patients. India's air pollution and biomass burning are contributing to a rise in asthma and food allergies, with asthma affecting about 37.9 million people.

Latin America and MEA: early-stage, with real constraints

Brazil, Mexico and Argentina are expanding diagnosis and treatment, although reimbursement limits and uneven access remain obstacles. In the Middle East and Africa, the UAE, Saudi Arabia and South Africa are growing with private healthcare expansion. Dust storms and air pollution in the UAE are lifting respiratory allergy burden and the need for long-term management such as allergen-specific immunotherapy.

Want the full data behind this story? Download a free sample of the Allergy Diagnostics and Therapeutics Market Report to see the market data points, trend analyses, and estimates and forecasts for yourself.

Key Industry Competitors

The market is highly competitive. Players are pursuing collaborations, product launches, acquisitions, digital and AI-powered diagnostics, and expansion into emerging regions. Companies profiled in the report include:

• Diagnostics-focused: R-Biopharm AG, Thermo Fisher Scientific, DASIT Group, EUROIMMUN (PerkinElmer), AESKU.GROUP, bioMérieux, Siemens Healthcare, HYCOR Biomedical, Omega Diagnostics, Lincoln Diagnostics, HOB Biotech, Danaher
• Therapeutics-focused and pharma: Stallergenes Greer, Allergy Therapeutics, AbbVie, Sanofi, Pfizer, Teva, GSK, Sun Pharma, Roche, Merck & Co., Astellas, Alcon
• Other: Minaris Medical America

Recent moves show the competitive dynamics:

• Consolidation: In January 2024, ALK acquired AllerQuest's business, making it the exclusive manufacturer and distributor of PRE-PEN in the U.S. and Canada. PRE-PEN is the only FDA-approved skin test for penicillin allergy.
• Label expansion: In January 2024, ALK received FDA approval to expand ODACTRA, a sublingual immunotherapy tablet for house dust mite allergic rhinitis, to adolescents aged 12 to 17.
• Pipeline deals: In October 2024, Astria Therapeutics licensed an OX40 portfolio, including STAR-0310 for atopic dermatitis and other allergic and immunological diseases.
• Local launches: In August 2025, Sanofi launched Allegra-D in India, a fixed-dose antihistamine and decongestant combination.

The report characterizes M&A activity as medium and product expansion as medium. Much of the innovation is in improving existing therapies rather than launching entirely new molecules.

The Investment & Business Perspective

1. Steady, durable demand with double-digit growth. A 10.0% CAGR to 2033, driven by environmental and demographic factors that are unlikely to reverse, gives this market a resilient demand base.
2. Two different risk and return profiles. Therapeutics offer scale and established revenue, with epinephrine as the entrenched product and immunotherapy and biologics as the innovation layer. Diagnostics offer the faster growth rate, with room for new entrants in multiplex, molecular and point-of-care testing.
3. Technology is the differentiator. AI-assisted interpretation, CRD, basophil activation testing and lab-on-a-chip platforms point to where value is being created. Companies that pair accuracy with convenience for patients and clinicians should be well positioned.
4. Selective M&A and partnership opportunities. With medium M&A intensity, niche assets such as specialized skin tests and validated food allergy diagnostics can become strategic targets for larger players.
5. Geographic sequencing matters. North America offers a mature, high-value market with fast regulatory pathways. Europe offers strong reimbursement but IVDR compliance requirements. Asia Pacific offers population-driven volume growth. Latin America and MEA offer long-term upside but carry reimbursement and access risk.
6. Regulatory exposure is a real consideration. The FDA, EMA and Japan's PMDA enforce strict standards for both diagnostics and therapeutics, so time to market and compliance cost belong in any business case.

Reaching allergists, hospitals and diagnostic labs starts with knowing where they are. Explore the U.S. Healthcare Facility Mapping & Intelligence Platform to identify and understand the facilities that make up the U.S. allergy care landscape.